

Caroline M Tanner

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4203544/caroline-m-tanner-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96
papers

10,446
citations

42
h-index

102
g-index

104
ext. papers

13,254
ext. citations

8.5
avg, IF

6.08
L-index

#	Paper	IF	Citations
96	The epidemiology of cognitive function in Parkinson's disease.. <i>Progress in Brain Research</i> , 2022 , 269, 3-37	2.9	0
95	Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.. <i>Npj Parkinson's Disease</i> , 2022 , 8, 29	9.7	0
94	Enhancing Clinical Information Display to Improve Patient Encounters: Human-Centered Design and Evaluation of the Parkinson Disease-BRIDGE Platform.. <i>JMIR Human Factors</i> , 2022 , 9, e33967	2.5	
93	Recruitment for Remote Decentralized Studies in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021 ,	5.3	1
92	The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. <i>Npj Parkinson's Disease</i> , 2021 , 7, 16	9.7	2
91	Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia. <i>Neurology and Therapy</i> , 2021 , 10, 307-320	4.6	2
90	Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 1972-1978	7	1
89	Bad Air and Parkinson Disease-The Fog May Be Lifting. <i>JAMA Neurology</i> , 2021 , 78, 793-795	17.2	
88	Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 308-320	5.3	6
87	Remote smartphone monitoring of Parkinson's disease and individual response to therapy. <i>Nature Biotechnology</i> , 2021 ,	44.5	11
86	Video-based Parkinson's disease assessments in a nationwide cohort of Fox Insight participants. <i>Clinical Parkinsonism & Related Disorders</i> , 2021 , 4, 100094	0.9	8
85	Dopamine transporter imaging predicts clinically-defined β synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 201-212	5.3	6
84	Remote telemedicine evaluation of deep brain stimulation candidacy: Retrospective cohort analysis. <i>Neurology: Clinical Practice</i> , 2020 , 10, 199-205	1.7	10
83	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. <i>Annals of Neurology</i> , 2020 , 88, 574-587	9.4	16
82	Translation, Validation, Diagnostic Accuracy, and Reliability of Screening Questionnaire for Parkinsonism in Three African Countries. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1113-1122	5.3	1
81	Reply to: Diagnostic Delay in Cervical Dystonia-Dystonia With Antecedent ET?. <i>Movement Disorders</i> , 2020 , 35, 1086-1087	7	
80	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. <i>Movement Disorders</i> , 2020 , 35, 833-844	7	18

79	Fox Insight collects online, longitudinal patient-reported outcomes and genetic data on Parkinson's disease. <i>Scientific Data</i> , 2020 , 7, 67	8.2	27
78	Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 677-691	5.3	10
77	Adrenoreceptors and the risk of Parkinson's disease. <i>Lancet Neurology</i> , 2020 , 19, 247-254	24.1	27
76	EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 543-558	5.3	12
75	Exploring the clinical burden of OFF periods in Parkinson disease. <i>American Journal of Managed Care</i> , 2020 , 26, S255-S264	2.1	2
74	Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. <i>CNS Spectrums</i> , 2020 , 1-10	1.8	9
73	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , 2020 , 19, 71-80	24.1	37
72	Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. <i>Clinics in Geriatric Medicine</i> , 2020 , 36, 1-12	3.8	143
71	Cervical dystonia incidence and diagnostic delay in a multiethnic population. <i>Movement Disorders</i> , 2020 , 35, 450-456	7	11
70	Electrocardiographic changes predate Parkinson's disease onset. <i>Scientific Reports</i> , 2020 , 10, 11319	4.9	9
69	Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020 , 35, 1755-1764	7	21
68	Current and projected future economic burden of Parkinson's disease in the U.S. <i>Npj Parkinson's Disease</i> , 2020 , 6, 15	9.7	78
67	Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP). <i>Frontiers in Aging Neuroscience</i> , 2020 , 12, 553635	5.3	12
66	The Impact of COVID-19 on Access to Parkinson's Disease Medication. <i>Movement Disorders</i> , 2020 , 35, 2129-2133	7	19
65	The Effect of the COVID-19 Pandemic on People with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1365-1377	5.3	56
64	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020 , 35, 1999-2008	7	32
63	Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 665-675	5.3	9
62	Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes". <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 245-246	3.6	

61	Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures. <i>Journal of Parkinson's Disease</i> , 2019 , 9, 665-679	5.3	8
60	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019 , 62, 201-209	3.6	9
59	A specific amino acid motif mediates risk and interacts with smoking history in Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 7419-7424	11.5	33
58	Concordance for Parkinson's disease in twins: A 20-year update. <i>Annals of Neurology</i> , 2019 , 85, 600-605	9.4	35
57	The NAS-NRC Twin Registry and Duke Twins Study of Memory in Aging: An Update. <i>Twin Research and Human Genetics</i> , 2019 , 22, 757-760	2.2	4
56	Longitudinal analyses of cerebrospinal fluid β synuclein in prodromal and early Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 1354-1364	7	48
55	A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 620-627	1.7	10
54	Association of brain heptachlor epoxide and other organochlorine compounds with lewy pathology. <i>Movement Disorders</i> , 2019 , 34, 228-235	7	6
53	The Microbiome in Neurodegenerative Disease. <i>Current Geriatrics Reports</i> , 2018 , 7, 81-91	1.3	5
52	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. <i>Movement Disorders</i> , 2018 , 33, 771-782	7	73
51	Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 183-190	2.2	11
50	Selected health and lifestyle factors, cytosine-adenine-guanine status, and phenoconversion in Huntington's disease. <i>Movement Disorders</i> , 2018 , 33, 472-478	7	16
49	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 102-106	3.6	42
48	The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1460-1477	5.3	142
47	Occupational exposures and parkinsonism among Shanghai women textile workers. <i>American Journal of Industrial Medicine</i> , 2018 , 61, 886-892	2.7	1
46	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017 , 32, 319-324	7	111
45	Caffeine, creatine, GRIN2A and Parkinson's disease progression. <i>Journal of the Neurological Sciences</i> , 2017 , 375, 355-359	3.2	17
44	Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , 2017 , 16, 620-629	24.1	98

43	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2017 , 74, 941-949	17.2	112
42	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17013	51.1	1700
41	Impaired Cognition and the Risk of Parkinson Disease: Trouble in Mind. <i>JAMA Neurology</i> , 2017 , 74, 1398-1400	14.0	5
40	Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID 3). <i>Movement Disorders</i> , 2017 , 32, 1701-1709	7.0	103
39	Virtual visits for Parkinson disease: A multicenter noncontrolled cohort. <i>Neurology: Clinical Practice</i> , 2017 , 7, 283-295	1.7	18
38	National Randomized Controlled Trial of Virtual House Calls for People with Parkinson Disease: Interest and Barriers. <i>Telemedicine Journal and E-Health</i> , 2016 , 22, 590-8	5.9	31
37	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. <i>JAMA Neurology</i> , 2016 , 73, 102-10	17.2	29
36	How stable are Parkinson disease subtypes in de novo patients: Analysis of the PPMI cohort?. <i>Parkinsonism and Related Disorders</i> , 2016 , 28, 62-7	3.6	89
35	Knowledge gaps and research recommendations for essential tremor. <i>Parkinsonism and Related Disorders</i> , 2016 , 33, 27-35	3.6	33
34	The best medicine? The influence of physical activity and inactivity on Parkinson disease. <i>Movement Disorders</i> , 2016 , 31, 1444-1454	7	64
33	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson Disease. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 53-58	2.2	1
32	Traumatic brain injury in later life increases risk for Parkinson disease. <i>Annals of Neurology</i> , 2015 , 77, 987-95	9.4	175
31	Natural history of multiple system atrophy in the USA: a prospective cohort study. <i>Lancet Neurology</i> , 2015 , 14, 710-9	24.1	169
30	Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 584-93	27.4	153
29	Parkinson disease research in a prospective cohort in China. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1200-4	3.6	19
28	Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. <i>Clinical Neuropharmacology</i> , 2015 , 38, 163-9	1.4	18
27	When brawn benefits brain: physical activity and Parkinson disease risk. <i>Brain</i> , 2015 , 138, 238-9	11.2	7
26	Dietary fat intake, pesticide use, and Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 82-7	3.6	81

25	The disease intersection of susceptibility and exposure: chemical exposures and neurodegenerative disease risk. <i>Alzheimer's and Dementia</i> , 2014 , 10, S213-25	1.2	55
24	Mendelian randomization of serum urate and parkinson disease progression. <i>Annals of Neurology</i> , 2014 , 76, 862-8	9.4	58
23	Association of cerebrospinal fluid Aβ ₁₋₄₂ , T-tau, P-tau181, and Synuclein levels with clinical features of drug-naive patients with early Parkinson disease. <i>JAMA Neurology</i> , 2013 , 70, 1277-87	17.2	252
22	Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. <i>JAMA Neurology</i> , 2013 , 70, 1382-8	17.2	29
21	Head injury, Synuclein Rep1, and Parkinson's disease. <i>Annals of Neurology</i> , 2012 , 71, 40-8	9.4	66
20	Pre-motor features of Parkinson's disease: the Honolulu-Asia Aging Study experience. <i>Parkinsonism and Related Disorders</i> , 2012 , 18 Suppl 1, S199-202	3.6	102
19	Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 1392-7	7	94
18	Solvent exposures and Parkinson disease risk in twins. <i>Annals of Neurology</i> , 2012 , 71, 776-84	9.4	97
17	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , 2011 , 95, 629-35	10.9	793
16	Rotenone, paraquat, and Parkinson's disease. <i>Environmental Health Perspectives</i> , 2011 , 119, 866-72	8.4	804
15	Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. <i>Archives of Neurology</i> , 2010 , 67, 1116-22		90
14	Advances in environmental epidemiology. <i>Movement Disorders</i> , 2010 , 25 Suppl 1, S58-62	7	60
13	Occupation and risk of parkinsonism: a multicenter case-control study. <i>Archives of Neurology</i> , 2009 , 66, 1106-13		160
12	Urate as a predictor of the rate of clinical decline in Parkinson disease. <i>Archives of Neurology</i> , 2009 , 66, 1460-8		265
11	Clinical features in early Parkinson disease and survival. <i>Archives of Neurology</i> , 2009 , 66, 1353-8		78
10	Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. <i>Movement Disorders</i> , 2008 , 23, 653-9; quiz 776	7	109
9	Nicotine and Parkinson's disease: implications for therapy. <i>Movement Disorders</i> , 2008 , 23, 1641-52	7	88
8	Association of olfactory dysfunction with risk for future Parkinson's disease. <i>Annals of Neurology</i> , 2008 , 63, 167-73	9.4	525

7	Association of olfactory dysfunction with incidental Lewy bodies. <i>Movement Disorders</i> , 2006 , 21, 2062-7	7	156
6	Head injury and Parkinson's disease risk in twins. <i>Annals of Neurology</i> , 2006 , 60, 65-72	9.4	191
5	Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. <i>American Journal of Epidemiology</i> , 2003 , 157, 1015-22	3.8	980
4	Parkinson's disease and motor-neuron disease in former prisoners-of-war. <i>Lancet, The</i> , 2000 , 355, 843	40	17
3	Parkinson disease in twins: an etiologic study. <i>JAMA - Journal of the American Medical Association</i> , 1999 , 281, 341-6	27.4	594
2	Epidemiology of Parkinson's disease. <i>Neurologic Clinics</i> , 1996 , 14, 317-35	4.5	413
1	The role of environmental toxins in the etiology of Parkinson's disease. <i>Trends in Neurosciences</i> , 1989 , 12, 49-54	13.3	236